OncoMatch/Clinical Trials/NCT07784387
A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal
Is NCT07784387 recruiting? Yes, currently enrolling (Sep 2026).
The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal. HR-NMIBC is an early-stage bladder cancer that is limited to the inner lining of bladder but has a considerable high chance of cancer coming back or worsening.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage TIS, TAG3, TAHG
Excluded: Stage TAG1, TAG2
Tumor stage N0/x and M0/x plus any of the following: Tis (primary CIS); TaG3/HG (high-grade non-invasive papillary carcinoma); or T1 (tumor invading subepithelial connective tissue)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07784387 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage TIS or TAG3 or TAHG is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages